VEGFR-2 expression in human melanoma: Revised assessment

International Journal of Cancer

Volumn 129, Issue 12, 2011, Pages 2807-2815

  Molhoek, Kerrington R ^a   Erdag, Gulsun ^a   Rasamny, Jk ^a   Murphy, Cheryl ^a   Deacon, Donna ^a   Patterson, James W ^a   Slingluff Jr , Craig L ^a   Brautigan, David L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

autocrine; bevacizumab; immunohistochemistry; siRNA; tissue microarray

Indexed keywords

SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2; ANTIBODY;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TISSUE MICROARRAY; VASCULAR ENDOTHELIUM; IMMUNOLOGY; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES; CELL LINE, TUMOR; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM METASTASIS; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84855172198     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25963     Document Type: Article

References (24)

1. Diepgen TL, Mahler V,. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl 61): 1-6.
2. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE,. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol 2008; 144 (4): 515-21. (Pubitemid 351581109)
3. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL, Jr,. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008; 68 (11): 4392-7.
4. Meyer RD, Mohammadi M, Rahimi N,. A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1. J Biol Chem 2006; 281 (2): 867-75.
5. Wissmann C, Detmar M,. Pathways targeting tumor lymphangiogenesis. Clin Cancer Res 2006; 12: 6865-8. (Pubitemid 44974477)
6. Rawlings NG, Simko E, Bebchuk T, Caldwell SJ, Singh B,. Localization of integrin alpha(v)beta3 and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in cutaneous and oral melanomas of dog. Histol Histopathol 2003; 18: 819-26. (Pubitemid 36773227)
7. Kim DW, Lu B, Hallahan DE,. Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr Opin Investig Drugs 2004; 5: 597-604.
8. Brunelleschi S, Penengo L, Santoro MM, Gaudino G,. Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des 2002; 8: 1959-72. (Pubitemid 34982163)
9. Salven P, Heikkila P, Joensuu H,. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930-4. (Pubitemid 27401946)
10. Gitay-Goren H, Halaban R, Neufeld G,. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993; 190: 702-8.
11. Straume O, Akslen LA,. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159: 223-35. (Pubitemid 33704207)
12. Pisacane AM, Risio M,. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Melanoma Res 2005; 15: 39-43. (Pubitemid 40354472)
13. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM,. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41: 375-84.
14. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005; 174: 6863-71. (Pubitemid 40705650)
15. Molhoek KR, Brautigan DL, Slingluff CL, Jr,. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005; 3: 39.
16. Darrow TL, Slingluff CL, Jr, Seigler HF,. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989; 142: 3329-35. (Pubitemid 19129962)
17. Hristov M, Erl W, Weber PC,. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003; 23: 1185-9. (Pubitemid 36871271)
18. Holmes K, Roberts OL, Thomas AM, Cross MJ,. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-12. (Pubitemid 47354167)
19. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. (Pubitemid 38618122)
20. Woo YL, Sterling J, Crawford R, van der Burg SH, Coleman N, Stanley M,. FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies. J Clin Pathol 2008; 61: 969-71.
21. Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkila P, Joensuu H, Alitalo K,. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 2008; 13: 554-6. (Pubitemid 351763905)
22. Brychtova S, Bezdekova M, Brychta T, Tichy M,. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 2008; 55: 273-9.
23. Gille J, Heidenreich R, Pinter A, Schmitz J, Boehme B, Hicklin DJ, Henschler R, Breier G,. Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. Int J Cancer 2007; 120: 1899-908. (Pubitemid 46418365)
24. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-34. (Pubitemid 46089673)